EsoBiotec Begins Clinical Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma
ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stage Early clinical data are expected in second half of 2025 MONT-SAINT-GUIBERT, Belgium, Dec. 11, 2024 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company empowering cells in …